Recovery & Support for Influenza | NYU Langone Health
NYU Langone doctors recommend watching for signs of influenza-related complications, such as symptoms that improve, and then return.
X-Ray Imaging | NYU Langone Health
NYU Langone offers bone, chest, abdominal, and dental X-rays.
NYU Langone Health App | NYU Langone Health
The NYU Langone Health app connects patients to their health information in MyChart on a mobile device, anywhere and anytime.
NYU Langone Health App | NYU Langone Health
The NYU Langone Health app connects patients to their health information in MyChart on a mobile device, anywhere and anytime.
Support for Asthma | NYU Langone Health
NYU Langone specialists provide long-term support to help you to manage asthma and prevent it from getting worse.
Diagnosing Rosacea | NYU Langone Health
Dermatologists at NYU Langone diagnose rosacea by examining your skin, evaluating your symptoms, and identifying triggers.
Surgery for Adult Congenital Heart Disease | NYU Langone Health
NYU Langone specialists sometimes perform surgery to treat adults with congenital heart disease.
Diagnosing Multiple Sclerosis | NYU Langone Health
NYU Langone doctors are experts at the complex process of diagnosing multiple sclerosis.
A Phase II Study of DRP-104 a glutamine antagonist in patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer and Gastroesophageal Cancer
This is a Phase 2 study testing a new medicine called DRP-104 (a glutamine antagonist) in patients with non-small cell lung cancer (NSCLC). These patients have changes or mutations in genes called NFE2L2 orKEAP1 and this makes their cancer harder to treat with chemotherapy and immunotherapy.The medicine DRP-104 works by blocking something called glutamine, which the cancer cells need to grow. This study will use a two step process to see if the medicine works well in the first group, before allowing other patients to join. In step one, patients will be given DRP-104 two times a week with at least three days betweeneach treatment, with no rest period between cycles (continuous schedule). If the results are promising and show this medicine is shrinking the tumors or stopping them from growing, more patients will be added in step two tocontinue testing the drug. All patients will have frequent medical check ups and blood samples taken to see how their bodies are handling the study medicine. The study team will have special scans done for all patients to see how the cancer isresponding to the study medicines. The study team will be monitoring the patients for potential side effects and safety concerns.
Randomized Controlled Open-Label Parallel Group Multi-Center Prospective Phase 4 Study Comparing the Efficacy of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2 3 and 4 Pressure Injuries
This post-marketing study is being performed to assess the effectiveness of Altrazeal® Transforming Powder Dressing (“Altrazeal®” or “TPD”) manufactured by ULURU Inc. in patients with pressure injuries (sometimes also referred to as pressure sores or decubitus ulcers) compared to the current Standard of Care (SOC) therapies. TPD is manufactured, marketed, and used in the United States of America (US). ULURU Inc. is registered with the US Food and Drug Administration (FDA) and Altrazeal® is listed as a Class I 510(k) exempt medical device: “dressing, wound, hydrogel without drug and/or biologic.” (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=410757&lpcd=NAE) Under the supervision of a health care professional, TPD may be used in surgical, acute or chronic wounds including pressure injuries.Objectives:Primary: To compare the efficacy of TPD in reducing primary dressing changes in the treatment of non-infected Stage 2, 3 and 4 pressure injuries (PrIs).Secondary: Evaluate: 1) wound healing trajectories2) safety in the form of adverse events3) subject pain for sensate patientsExploratory: Evaluate: 1) resource utilization of TPD relative to SOC2) cost-effectiveness of TPD versus SOC3) budget impact analysis of adopting TPD4) wound quality of life5) research subject satisfaction6) other ad-hoc analyses as warranted